Show simple item record

dc.contributor.authorAndre, T
dc.contributor.authorSaunders, Mark P
dc.contributor.authorKanehisa, A
dc.contributor.authorGandossi, E
dc.contributor.authorFougeray, R
dc.contributor.authorCausse-Amellal, N
dc.contributor.authorFalcone, A
dc.date.accessioned2019-12-09T17:23:30Z
dc.date.available2019-12-09T17:23:30Z
dc.date.issued2019en
dc.identifier.citationAndre T, Saunders MP, Kanehisa A, Gandossi E, Fougeray R, Causse-Amellal N, et al. 665TiP SOLSTICE, a phase III, randomized, open label study of trifluridine/tipiracil+bevacizumab (bev) versus capecitabine+bev for the 1L treatment of patients with unresectable metastatic colorectal cancer (mCRC) who are not candidates for intensive therapy. Annals of Oncology. 2019;30(Supplement_5):250.en
dc.identifier.doi10.1093/annonc/mdz246.142en
dc.identifier.urihttp://hdl.handle.net/10541/622584
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1093/annonc/mdz246.142en
dc.titleSOLSTICE, a phase III, randomized, open label study of trifluridine/tipiracil plus bevacizumab (bev) versus capecitabine plus bev for the 1L treatment of patients with unresectable metastatic colorectal cancer (mCRC) who are not candidates for intensive therapyen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentMedical Oncology, Hopital Saint-Antoine, Paris,en
dc.identifier.journalAnnals of Oncologyen
refterms.dateFOA2020-01-21T19:55:16Z


Files in this item

Thumbnail
Name:
mdz246.142.pdf
Size:
81.73Kb
Format:
PDF
Description:
From UNPAYWALL. Conference abstract

This item appears in the following Collection(s)

Show simple item record